Rapport Therapeutics Q4 2025 Earnings Report

Rapport Therapeutics EPS Results

• Actual EPS: -$0.72
• Consensus EPS: -$0.65
• Beat/Miss: Missed by -$0.07
• One Year Ago EPS: N/A

Rapport Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rapport Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/10/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Rapport Therapeutics (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation. Its diverse pipeline includes antibody-based constructs and small-molecule inhibitors targeting both solid tumors and hematologic malignancies. Preclinical data have demonstrated promising anti-tumor activity and favorable safety profiles, supporting the advancement of several programs toward first-in-human studies.

Headquartered in Massachusetts, Rapport Therapeutics collaborates with academic institutions, contract research organizations and industry partners to drive its research and development efforts. The company is led by a management team with extensive experience in oncology drug development, clinical operations and regulatory strategy. With a strategic focus on translating scientific insights into innovative cancer therapies, Rapport aims to improve outcomes for patients worldwide.